Vitamin D and cancer mortality: what the VITAL extended follow-up shows

← Back to articles

When the VITAL trial first reported in late 2018, the headline was that 2,000 IU/day of vitamin D3 did not lower the incidence of invasive cancer in a generally vitamin-D-replete population. That read as a negative result. Less attention went to a pre-specified secondary endpoint — death from cancer — and to the trial's later, longer-latency analyses, which together tell a more nuanced story. Incidence and mortality are not the same outcome, and vitamin D appears to behave differently on each.

What VITAL actually tested

VITAL randomized 25,871 U.S. adults — men aged 50 and older, women 55 and older, none with cancer or cardiovascular disease at entry — to vitamin D3 2,000 IU/day, marine omega-3 fatty acids 1 g/day, both, or neither, in a 2×2 factorial design over a median 5.3 years [1]. Critically, participants were not selected for vitamin D deficiency. This was a test of adding vitamin D to a largely replete population, not of correcting a deficiency — a distinction that shapes how far the results generalize.

The primary result: no effect on incidence

For the primary endpoint, total invasive cancer, vitamin D did nothing: 793 cancers in the vitamin D group versus 824 on placebo, a hazard ratio of 0.96 (95% CI 0.88–1.06) [1]. The companion omega-3 comparison was also null for total cancer (HR 1.03, 95% CI 0.93–1.13) [2]. On the question of whether vitamin D stops cancer from forming, VITAL is, fairly read, a clear negative.

The mortality signal

Death from cancer was a pre-specified secondary endpoint. Across the full intervention period there were 341 cancer deaths, with a hazard ratio of 0.83 (95% CI 0.67–1.02) favoring vitamin D — a 17% relative reduction that did not reach statistical significance, the confidence interval crossing 1.0 [1]. Because cancers present and progress over years, the investigators also examined longer-latency effects. A secondary analysis published in 2020 used a composite of advanced cancer — metastatic or fatal disease — and found a significant reduction: 226 events on vitamin D versus 274 on placebo, HR 0.83 (95% CI 0.69–0.99) [3]. The mortality and advanced-cancer signals point the same way even though incidence does not.

The body-weight interaction

The most consistent modifier across VITAL's analyses is body weight. In the advanced-cancer analysis, the benefit was concentrated in participants with normal body-mass index (BMI under 25: HR 0.62, 95% CI 0.45–0.86) and absent in those with overweight or obesity (BMI 25 to under 30: HR 0.89; BMI 30 or higher: HR 1.05), a statistically significant interaction [3]. The same pattern appears in pooled data: a meta-analysis of randomized trials found that, among trials using daily dosing, the reduction in cancer incidence was limited to normal-weight individuals (summary relative risk 0.76, 95% CI 0.64–0.90), with no benefit in heavier participants [4]. Why this happens is not settled — proposed explanations include sequestration of fat-soluble vitamin D in adipose tissue and differences in achieved blood levels at a fixed dose — but the signal is reproducible enough to take seriously.

What the meta-analyses add

VITAL is the largest single trial, but it is not alone. A 2019 meta-analysis of randomized trials reported a null effect on total cancer incidence (relative risk 0.98, 95% CI 0.93–1.03) but a significant reduction in cancer mortality (RR 0.87, 95% CI 0.79–0.96), an effect "largely attributable to interventions with daily dosing" rather than infrequent large boluses [5]. An updated 2022 analysis reached the same conclusion: no effect on incidence overall, but daily — not bolus — supplementation reduced cancer mortality (summary RR among daily-dosing trials 0.87, 95% CI 0.78–0.96) [4]. The roughly 13% relative reduction in cancer death is one of the more reproducible findings in the vitamin D literature, and the daily-versus-bolus distinction matters: high intermittent doses do not show the same effect.

How to read this in 2026

The honest summary is narrow but real. Vitamin D does not appear to prevent cancer from occurring. It may modestly reduce the chance that a cancer becomes lethal, most clearly with daily (not bolus) dosing and most clearly in people who are not overweight. The effect sizes are small, the confidence intervals in the single trial brush against the null, and the population studied was already largely replete — so this is a reason for measured optimism, not a treatment claim. For an adult with a 25-hydroxyvitamin D level in the deficient or insufficient range, correcting that deficiency with a routine daily dose (commonly 1,000–2,000 IU) is reasonable and supported by broader evidence. Chasing very high blood levels, taking infrequent megadoses, or using vitamin D to treat a diagnosed cancer are not supported by these data. Anyone with a cancer diagnosis should make supplement decisions with their oncology team, not on the basis of a secondary endpoint.

Sources

1. Manson JE, Cook NR, Lee IM, et al. "Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease." New England Journal of Medicine, 2019;380(1):33–44. PMID 30415629.
2. Manson JE, Cook NR, Lee IM, et al. "Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer." New England Journal of Medicine, 2019;380(1):23–32. PMID 30415637.
3. Chandler PD, Chen WY, Ajala ON, et al. "Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial." JAMA Network Open, 2020;3(11):e2025850. PMID 33206192.
4. Keum N, Chen QY, Lee DH, Manson JE, Giovannucci E. "Vitamin D supplementation and total cancer incidence and mortality by daily vs. infrequent large-bolus dosing strategies: a meta-analysis of randomised controlled trials." British Journal of Cancer, 2022;127(5):872–878. PMID 35676320.
5. Keum N, Lee DH, Greenwood DC, Manson JE, Giovannucci E. "Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials." Annals of Oncology, 2019;30(5):733–743. PMID 30796437.